Choate Investment Advisors Lowers Stock Holdings in Kronos Bio, Inc. (NASDAQ:KRON)

Choate Investment Advisors reduced its stake in Kronos Bio, Inc. (NASDAQ:KRON) by 11.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 274,787 shares of the company’s stock after selling 33,910 shares during the quarter. Choate Investment Advisors owned about 0.46% of Kronos Bio worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Peapod Lane Capital LLC purchased a new stake in Kronos Bio in the fourth quarter valued at approximately $534,000. 64.09% of the stock is owned by institutional investors.

Kronos Bio Price Performance

Shares of KRON opened at $0.95 on Tuesday. The firm’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $0.96. The company has a market capitalization of $57.32 million, a P/E ratio of -0.66 and a beta of 1.79. Kronos Bio, Inc. has a 1-year low of $0.69 and a 1-year high of $1.60.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.